Annual Cash & Cash Equivalents
$37.43 M
-$5.01 M-11.81%
December 31, 2023
Summary
- As of February 10, 2025, ABIO annual cash & cash equivalents is $37.43 million, with the most recent change of -$5.01 million (-11.81%) on December 31, 2023.
- During the last 3 years, ABIO annual cash & cash equivalents has fallen by -$11.64 million (-23.72%).
Performance
ABIO Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$33.28 M
-$2.62 M-7.30%
June 30, 2024
Summary
- As of February 10, 2025, ABIO quarterly cash and cash equivalents is $33.28 million, with the most recent change of -$2.62 million (-7.30%) on June 30, 2024.
- Over the past year, ABIO quarterly cash and cash equivalents has dropped by -$4.15 million (-11.08%).
Performance
ABIO Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ABIO Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -11.8% | -11.1% |
| 3 y3 years | -23.7% | -42.9% |
| 5 y5 years | +466.4% | -42.9% |
ABIO Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -29.9% | at low | -37.6% | at low |
| 5 y | 5-year | -29.9% | -77.7% | -50.3% | -79.9% |
| alltime | all time | -38.0% | -94.1% | -80.0% | -94.0% |
ARCA Biopharma Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2024 | - | $33.28 M(-7.3%) |
| Mar 2024 | - | $35.90 M(-4.1%) |
| Dec 2023 | $37.43 M(-11.8%) | $37.43 M(-2.7%) |
| Sep 2023 | - | $38.49 M(-4.2%) |
| Jun 2023 | - | $40.16 M(-1.7%) |
| Mar 2023 | - | $40.85 M(-3.8%) |
| Dec 2022 | $42.45 M(-20.5%) | $42.45 M(-3.4%) |
| Sep 2022 | - | $43.94 M(-5.4%) |
| Jun 2022 | - | $46.44 M(-5.3%) |
| Mar 2022 | - | $49.06 M(-8.1%) |
| Dec 2021 | $53.36 M(+8.7%) | $53.36 M(-8.5%) |
| Sep 2021 | - | $58.31 M(-7.7%) |
| Jun 2021 | - | $63.20 M(-5.6%) |
| Mar 2021 | - | $66.93 M(+36.4%) |
| Dec 2020 | $49.07 M(+486.8%) | $49.07 M(-4.0%) |
| Sep 2020 | - | $51.09 M(+362.8%) |
| Jun 2020 | - | $11.04 M(+65.4%) |
| Mar 2020 | - | $6.67 M(-20.2%) |
| Dec 2019 | $8.36 M(+26.6%) | $8.36 M(-13.3%) |
| Sep 2019 | - | $9.64 M(-3.2%) |
| Jun 2019 | - | $9.97 M(+24.5%) |
| Mar 2019 | - | $8.01 M(+21.2%) |
| Dec 2018 | $6.61 M(-24.1%) | $6.61 M(-18.0%) |
| Sep 2018 | - | $8.06 M(-16.4%) |
| Jun 2018 | - | $9.63 M(-20.3%) |
| Mar 2018 | - | $12.10 M(+39.0%) |
| Dec 2017 | $8.70 M(+17.6%) | $8.70 M(+6.9%) |
| Sep 2017 | - | $8.14 M(-10.5%) |
| Jun 2017 | - | $9.10 M(+47.5%) |
| Mar 2017 | - | $6.17 M(-16.6%) |
| Dec 2016 | $7.40 M(-80.9%) | $7.40 M(-8.6%) |
| Sep 2016 | - | $8.10 M(-43.7%) |
| Jun 2016 | - | $14.38 M(-51.6%) |
| Mar 2016 | - | $29.72 M(-23.4%) |
| Dec 2015 | $38.80 M(+152.7%) | $38.80 M(-6.5%) |
| Sep 2015 | - | $41.48 M(-5.9%) |
| Jun 2015 | - | $44.09 M(+261.8%) |
| Mar 2015 | - | $12.18 M(-20.6%) |
| Dec 2014 | $15.35 M(-8.4%) | $15.35 M(-11.0%) |
| Sep 2014 | - | $17.25 M(-11.0%) |
| Jun 2014 | - | $19.38 M(-8.6%) |
| Mar 2014 | - | $21.20 M(+26.5%) |
| Dec 2013 | $16.76 M(+473.8%) | $16.76 M(-10.1%) |
| Sep 2013 | - | $18.63 M(-8.6%) |
| Jun 2013 | - | $20.37 M(+476.0%) |
| Mar 2013 | - | $3.54 M(+21.1%) |
| Dec 2012 | $2.92 M(-50.9%) | $2.92 M(-5.2%) |
| Sep 2012 | - | $3.08 M(-3.2%) |
| Jun 2012 | - | $3.18 M(-24.7%) |
| Mar 2012 | - | $4.23 M(-28.9%) |
| Dec 2011 | $5.94 M(-15.4%) | $5.94 M(+3.4%) |
| Sep 2011 | - | $5.75 M(-23.0%) |
| Jun 2011 | - | $7.46 M(+46.8%) |
| Mar 2011 | - | $5.08 M(-27.6%) |
| Dec 2010 | $7.03 M | $7.03 M(-11.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2010 | - | $7.91 M(-20.3%) |
| Jun 2010 | - | $9.92 M(+114.3%) |
| Mar 2010 | - | $4.63 M(-40.4%) |
| Dec 2009 | $7.76 M(+0.3%) | $7.76 M(-27.1%) |
| Sep 2009 | - | $10.64 M(-44.0%) |
| Jun 2009 | - | $19.01 M(-26.6%) |
| Mar 2009 | - | $25.92 M(+234.9%) |
| Dec 2008 | $7.74 M(-75.9%) | $7.74 M(-78.0%) |
| Sep 2008 | - | $35.17 M(-17.7%) |
| Jun 2008 | - | $42.71 M(+12.5%) |
| Mar 2008 | - | $37.97 M(+18.4%) |
| Dec 2007 | $32.06 M(-46.9%) | $32.06 M(-29.0%) |
| Sep 2007 | - | $45.13 M(+11.9%) |
| Jun 2007 | - | $40.32 M(-39.7%) |
| Mar 2007 | - | $66.86 M(+10.8%) |
| Dec 2006 | $60.34 M(+59.8%) | $60.34 M(-40.9%) |
| Sep 2006 | - | $102.06 M(-24.3%) |
| Jun 2006 | - | $134.79 M(-18.8%) |
| Mar 2006 | - | $166.01 M(+339.6%) |
| Dec 2005 | $37.76 M(+124.6%) | $37.76 M(+12.6%) |
| Sep 2005 | - | $33.55 M(-30.0%) |
| Jun 2005 | - | $47.93 M(-28.4%) |
| Mar 2005 | - | $66.97 M(+298.4%) |
| Dec 2004 | $16.81 M(+27.9%) | $16.81 M(+746.5%) |
| Sep 2004 | - | $1.99 M(-89.7%) |
| Jun 2004 | - | $19.27 M(-76.1%) |
| Mar 2004 | - | $80.64 M(+513.7%) |
| Dec 2003 | $13.14 M(+490.6%) | $13.14 M(-5.2%) |
| Sep 2003 | - | $13.86 M(-32.5%) |
| Jun 2003 | - | $20.54 M(-18.8%) |
| Mar 2003 | - | $25.29 M(+1036.4%) |
| Dec 2002 | $2.23 M(-82.0%) | $2.23 M(-47.9%) |
| Sep 2002 | - | $4.27 M(-63.9%) |
| Jun 2002 | - | $11.83 M(+82.5%) |
| Mar 2002 | - | $6.49 M(-47.4%) |
| Dec 2001 | $12.33 M(+356.8%) | $12.33 M(-25.4%) |
| Sep 2001 | - | $16.53 M(+160.7%) |
| Jun 2001 | - | $6.34 M(-57.2%) |
| Mar 2001 | - | $14.81 M(+448.9%) |
| Dec 2000 | $2.70 M(-80.3%) | $2.70 M(-77.2%) |
| Sep 2000 | - | $11.84 M(-19.2%) |
| Jun 2000 | - | $14.66 M(-42.4%) |
| Mar 2000 | - | $25.43 M(+85.6%) |
| Dec 1999 | $13.70 M(-36.6%) | $13.70 M(-16.5%) |
| Sep 1999 | - | $16.40 M(-5.2%) |
| Jun 1999 | - | $17.30 M(+5.5%) |
| Mar 1999 | - | $16.40 M(-24.1%) |
| Dec 1998 | $21.60 M(-6.9%) | $21.60 M(+103.8%) |
| Sep 1998 | - | $10.60 M(-7.8%) |
| Jun 1998 | - | $11.50 M(-64.8%) |
| Mar 1998 | - | $32.70 M(+40.9%) |
| Dec 1997 | $23.20 M(+246.3%) | $23.20 M(-41.1%) |
| Sep 1997 | - | $39.40 M(+183.5%) |
| Jun 1997 | - | $13.90 M(+195.7%) |
| Mar 1997 | - | $4.70 M |
| Dec 1996 | $6.70 M | - |
FAQ
- What is ARCA biopharma annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for ARCA biopharma?
- What is ARCA biopharma annual cash & cash equivalents year-on-year change?
- What is ARCA biopharma quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for ARCA biopharma?
- What is ARCA biopharma quarterly cash and cash equivalents year-on-year change?
What is ARCA biopharma annual cash & cash equivalents?
The current annual cash & cash equivalents of ABIO is $37.43 M
What is the all time high annual cash & cash equivalents for ARCA biopharma?
ARCA biopharma all-time high annual cash & cash equivalents is $60.34 M
What is ARCA biopharma annual cash & cash equivalents year-on-year change?
Over the past year, ABIO annual cash & cash equivalents has changed by -$5.01 M (-11.81%)
What is ARCA biopharma quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ABIO is $33.28 M
What is the all time high quarterly cash and cash equivalents for ARCA biopharma?
ARCA biopharma all-time high quarterly cash and cash equivalents is $166.01 M
What is ARCA biopharma quarterly cash and cash equivalents year-on-year change?
Over the past year, ABIO quarterly cash and cash equivalents has changed by -$4.15 M (-11.08%)